Sally R. Ellingson

University of Kentucky — United States

Computer Science · Physical Sciences

18h-index1.1kcitations58works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(27), Protein Structure and Dynamics(13), Bioinformatics and Genomic Networks(8), Lung Cancer Treatments and Mutations(5), Gene expression and cancer classification(5)

Publications57 total

Link Prediction in Multipartite Graphs With Application to Drug Repositioning Studies
IEEE Transactions on Computational Biology and Bioinformatics·2025Open Access
In-Silico Predictions of Drug Resistance in Lung Cancers with EGFR Mutation
2025· 1 citedOpen Access
Result-scalability: Following the evolution of selected social impact of HPC
The International Journal of High Performance Computing Applications·2025· 1 citedOpen Access
Abstract 2535: Uncovering bias in AI-based digital pathology analysis
Cancer Research·2025
Artesunate enhances the efficacy of enzalutamide in advanced prostate cancer
Journal of Biological Chemistry·2025Open Access
The algebraic extended atom-type graph-based model for precise ligand–receptor binding affinity prediction
Journal of Cheminformatics·2025· 4 citedOpen Access
S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance
International Journal of Biological Sciences·2024· 3 citedOpen Access
<scp>L858R</scp> / <scp>L718Q</scp> and <scp>L858R</scp> / <scp>L792H</scp> Mutations of <scp>EGFR</scp> Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds
Proteins Structure Function and Bioinformatics·2024· 4 citedOpen Access
Author response for "&lt;scp&gt;L858R&lt;/scp&gt;/&lt;scp&gt;L718Q&lt;/scp&gt; and &lt;scp&gt;L858R&lt;/scp&gt;/&lt;scp&gt;L792H&lt;/scp&gt; Mutations of &lt;scp&gt;EGFR&lt;/scp&gt; Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds"
2024
L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds
2024Open Access
The Algebraic Extended Atom-type Graph-Based Model for Precise Ligand--Receptor Binding Affinity Prediction
2024Open Access
Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells
Scientific Reports·2023· 8 citedOpen Access
Open Data and transparency in artificial intelligence and machine learning: A new era of research
F1000Research·2023· 28 citedOpen Access
Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition.
PubMed·2023· 2 citedOpen Access
Artesunate acts through cytochrome c to inhibit growth of pediatric AML cells
Research Square (Research Square)·2022· 1 citedOpen Access
The RelB-BLNK Axis Determines Cellular Response to a Novel Redox-Active Agent Betamethasone during Radiation Therapy in Prostate Cancer
International Journal of Molecular Sciences·2022· 4 citedOpen Access
Gene-disease-drug link prediction using tripartite graphs
2021· 1 cited
KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer
Cancers·2021· 18 citedOpen Access
Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19
Journal of Chemical Information and Modeling·2020· 186 citedOpen Access
Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19
2020· 23 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Jérôme Baudry(13), Jeremy C. Smith(11), David W. Fardo(5), Hunter Moseley(4), Wibe A. de Jong(4), Christine F. Brainson(4), Michael A. Langston(4), Atanu Acharya(3), Rupesh Agarwal(3), Matthew Baker(3), Debsindhu Bhowmik(3), Kendall Byler(3), Leighton Coates(3), Connor J. Cooper(3), Omar Demerdash(3), Isabella Daidone(3), John D. Eblen(3), Stefano Forli(3), Jens Gläser(3), James C. Gumbart(3)